+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Non Small Cell Lung Cancer Drug"

From
From
Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • January 2020
  • 658 Pages
  • Global
From
Non-Small Cell Lung Cancer - Pipeline Review, H1 2020 - Product Thumbnail Image

Non-Small Cell Lung Cancer - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 4664 Pages
  • Global
From
From
From
From
Loading Indicator

The Non Small Cell Lung Cancer Drug market is a subset of the larger Lung Cancer Drug market. Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is typically treated with chemotherapy, radiation, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to healthy cells. The Non Small Cell Lung Cancer Drug market is highly competitive, with a number of companies offering various treatments. Companies such as AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer are some of the major players in the market. Other companies such as Amgen, Boehringer Ingelheim, and Novartis are also active in the market. Show Less Read more